Alethea Capital Management LLC Increases Stake in Neuralstem, Inc. (CUR)

Alethea Capital Management LLC boosted its stake in Neuralstem, Inc. (NASDAQ:CUR) by 100.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 328,788 shares of the company’s stock after buying an additional 164,394 shares during the period. Neuralstem comprises 1.1% of Alethea Capital Management LLC’s investment portfolio, making the stock its 29th largest position. Alethea Capital Management LLC owned approximately 2.76% of Neuralstem worth $1,904,000 at the end of the most recent reporting period.

Receive News & Ratings for Neuralstem Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Separately, Blair William & Co. IL raised its stake in Neuralstem by 171.0% in the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock valued at $506,000 after buying an additional 55,115 shares during the period. 14.09% of the stock is owned by institutional investors and hedge funds.

Neuralstem, Inc. (NASDAQ CUR) traded down 0.85% during midday trading on Tuesday, reaching $1.16. The company’s stock had a trading volume of 6,896 shares. The firm’s market capitalization is $14.06 million. The company’s 50-day moving average is $3.21 and its 200 day moving average is $4.33. Neuralstem, Inc. has a 52 week low of $0.99 and a 52 week high of $6.60.

Neuralstem (NASDAQ:CUR) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%. Analysts expect that Neuralstem, Inc. will post ($2.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “[[title]]” was first published by [[site]] and is the property of of [[site]]. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at [[permalink]].

Separately, ValuEngine upgraded Neuralstem from a “sell” rating to a “hold” rating in a research note on Friday, June 9th.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.